胃癌免疫治疗研究进展OA北大核心CSTPCD

Currently,chemotherapy combined with immune checkpoint inhibitors(ICIs)has become one of the important treatments for advanced gastric cancer or adenocarcinoma of esophagogastric junction.However,the effectiveness of this ap-proach in locally advanced gastric cancer has still not been val-idated by higher-level studies.The combination of molecular markers and personalised tests may be an effective means of screening the population for the benefits of immunotherapy in gastric cancer;The neoadjuvant immunotherapy regimen should take into account the specific type of tumour,molecular characteristics,and the patient's overall health status.Rou-tine evaluation after 2-4 cycles of neoadjuvant therapy com-bined with multidisciplinary team discussion can grasp the best timing during the whole treatment process and maintain the best interests of patients;The evaluation of the efficacy of neoadjuvant immunotherapy requires comprehensive judg-ment,and imaging and pathological evaluation are still subject to great controversy;The surgical interval of 4-6 weeks after neoadjuvant immunotherapy may be the optimal timing of sur-gery.The choice of surgery should take into account the loca-tion and size of the tumour,the patient's overall health status,and technical feasibility.Careful management and effective in-tervention of adverse events(IrAEs)during neoadjuvant immu-notherapy will help to improve the patient's outcome,and cli-nicians should closely monitor the patient's physical response throughout the course of the treatment and adjust the treatment regimen accordingly to ensure the best-balanced outcome.